Biopharmaceutical company
Appears in 5 stories · Last updated Oct 26, 2026
Developer and marketer of IMDELLTRA (tarlatamab)
Small cell lung cancer that has spread through the chest and beyond has held median survival near a year for decades. A phase 3 trial presented Oct. 24 at the ESMO Congress raised that to 21.1 months, about eight months longer than the comparison arm.
Updated Oct 26
Markets Tepezza, the current TED sales leader; developing subcutaneous formulation
The FDA approved Roche's Enspryng for thyroid eye disease on October 15, the first and only at-home subcutaneous treatment for the condition. Patients or caregivers inject the drug with a prefilled syringe or pen after a healthcare provider's training, with no infusion clinic visits.
Updated Oct 17
As of September 2026: Competitor with an already-approved SCLC treatment
Merck and Daiichi Sankyo withdrew their US application for ifinatamab deruxtecan, an experimental antibody-drug conjugate for extensive-stage small cell lung cancer, an aggressive disease that has resisted most new treatments. The FDA had told the companies their Phase 2 data were not enough to support accelerated approval, and the bid was pulled on September 25.
Updated Sep 29
As of September 2026: Sponsor of the dazodalibep phase 3 program
Sjögren's disease has no approved treatment in the US. Amgen just moved a step closer to ending that.
Updated Sep 22
As of May 2026: Developer of tarlatamab and originator of the BiTE platform
For decades, patients with extensive-stage small-cell lung cancer who relapsed after chemotherapy had almost nowhere to turn — five-year survival rates sat around 3%. Now a drug that bridges the patient's immune cells to their tumor has won approval in both the United States and China.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
